CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Virus Inactivation in the 1990s ? and into the 21st Century: Part 5: Disinfection
by Gail Sofer, BioReliance Both the process and the product strongly influence viral inactivation, and unknown or unspecified details ? such as variability in virus titers, measuring devices, calibrations, and protocols ? can all influence log reduction values. This article series covers what you need to know to fully understand the properties of the test article, the viruses inactivated, and the critical control parameters for selected inactivation methods.
Advertisement
Articles in this issue
over 23 years ago
Becoming a Partner of Choice and Evaluating Prospective Alliancesover 23 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counselorover 23 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechover 23 years ago
Survival Strategies: Keeping Tabs on Trainingover 23 years ago
Outsourcing Outlook: Contract Services' Crystal BallAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement